Cargando…

HS-543 induces apoptosis of Imatinib-resistant chronic myelogenous leukemia with T315I mutation

Chronic myeloid leukemia (CML) is characterized by a constitutive activation of Bcr-Abl tyrosine kinase. Bcr-Abl/T315I is the predominant mutation that causes resistance to Imatinib. In the present study, we synthesized a novel Bcr-Abl inhibitor, HS-543, and investigated its effect on cell survival...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Soo Jung, Jung, Kyung Hee, Yan, Hong Hua, Son, Mi Kwon, Fang, Zhenghuan, Ryu, Ye-Lim, Lee, Hyunseung, Lim, Joo Han, Suh, Jun-Kyu, Kim, JinHee, Lee, Soyoung, Hong, Sungwoo, Hong, Soon-Sun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2014
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4359310/ https://www.ncbi.nlm.nih.gov/pubmed/25483100

Ejemplares similares

HS-173, a Novel PI3K Inhibitor, Attenuates the Activation of Hepatic Stellate Cells in Liver Fibrosis
por: Son, Mi Kwon, et al.
Publicado: (2013)

HS-173, a novel PI3K inhibitor suppresses EMT and metastasis in pancreatic cancer
por: Rumman, Marufa, et al.
Publicado: (2016)

HS-133, a novel fluorescent phosphatidylinositol 3-kinase inhibitor as a potential imaging and anticancer agent for targeted therapy
por: Lee, Ju-Hee, et al.
Publicado: (2014)

Radiosensitization of the PI3K inhibitor HS-173 through reduction of DNA damage repair in pancreatic cancer
por: Park, Jung Hee, et al.
Publicado: (2017)

HS-1371, a novel kinase inhibitor of RIP3-mediated necroptosis
por: Park, Han-Hee, et al.
Publicado: (2018)

The treatment of pediatric chronic myelogenous leukemia in the imatinib era
por: Lee, Jae Wook, et al.
Publicado: (2011)

Crizotinib Exhibits Antitumor Activity by Targeting ALK Signaling not c-MET in Pancreatic Cancer
por: Yan, Hong Hua, et al.
Publicado: (2014)

Pristimerin induces apoptosis in imatinib-resistant chronic myelogenous leukemia cells harboring T315I mutation by blocking NF-κB signaling and depleting Bcr-Abl
por: Lu, Zhongzheng, et al.
Publicado: (2010)

Synthesis and Biological Evaluation of BODIPY-PF-543
por: Shrestha, Jitendra, et al.
Publicado: (2019)

A Case of Isolated Lymphoblastic Relapse of the Central Nervous System in a Patient with Chronic Myelogenous Leukemia Treated with Imatinib
por: Park, Mi-Jung, et al.
Publicado: (2014)

Correction to: Pristimerin induces apoptosis in imatinib-resistant chronic myelogenous leukemia cells harboring T315I mutation by blocking NF-κB signaling and depleting Bcr-Abl
por: Lu, Zhongzheng, et al.
Publicado: (2021)

Efficacy of imatinib mesylate-based front-line therapy in pediatric chronic myelogenous leukemia
por: Oh, Hyun Jin, et al.
Publicado: (2013)

A Dansyl-Modified Sphingosine Kinase Inhibitor DPF-543 Enhanced De Novo Ceramide Generation
por: Shamshiddinova, Maftuna, et al.
Publicado: (2021)

Imatinib Therapy in Chronic Myelogenous Leukemia and Thyroid Function Tests
por: Mashhadi, Mohammad Ali, et al.
Publicado: (2014)

MEK blockade overcomes the limited activity of palbociclib in head and neck cancer
por: Fang, Zhenghuan, et al.
Publicado: (2020)

A case of chronic myelogenous leukemia with the T315I mutation who progressed to myeloid blast phase and was successfully treated with asciminib
por: Tomassetti, Sarah, et al.
Publicado: (2022)

Characterizing of Four Common BCR-ABL Kinase Domain Mutations (T315I, Y253H, M351T and E255K) in Iranian Chronic Myelogenous Leukemia Patients With Imatinib Resistance
por: Rejali, Leili, et al.
Publicado: (2015)

Selonsertib Inhibits Liver Fibrosis via Downregulation of ASK1/MAPK Pathway of Hepatic Stellate Cells
por: Yoon, Young-Chan, et al.
Publicado: (2020)

Farnesiferol C Induces Apoptosis in Chronic Myelogenous Leukemia Cells as an Imatinib Sensitizer via Caspase Activation and HDAC (Histone Deacetylase) Inactivation
por: Jung, Ji Hoon, et al.
Publicado: (2019)

Selective Bowel Decontamination for the Prevention of Infection in Acute Myelogenous Leukemia: A Prospective Randomized Trial
por: Lee, Dong Gun, et al.
Publicado: (2002)

Differentiation of imatinib -resistant chronic myeloid leukemia cells with BCR-ABL-T315I mutation induced by Jiyuan Oridonin A
por: Xu, Yun, et al.
Publicado: (2023)

Translocation of heme oxygenase-1 contributes to imatinib resistance in chronic myelogenous leukemia
por: Schaefer, Bianca, et al.
Publicado: (2017)

Homoharringtonine enhances the effect of imatinib on chronic myelogenous leukemia cells by downregulating ZFX
por: Wu, Jingjing, et al.
Publicado: (2019)

Synthesis of Gemcitabine-Threonine Amide Prodrug Effective on Pancreatic Cancer Cells with Improved Pharmacokinetic Properties
por: Hong, Sungwoo, et al.
Publicado: (2018)

Primo Vascular System Accompanying a Blood Vessel from Tumor Tissue and a Method to Distinguish It from the Blood or the Lymph System
por: Lim, Jaekwan, et al.
Publicado: (2013)

PBT-6, a Novel PI3KC2γ Inhibitor in Rheumatoid Arthritis
por: Kim, Juyoung, et al.
Publicado: (2020)

Multiple Granulocytic Sarcomas in a Patient with Longstanding Complete Remission of Acute Myelogenous Leukemia
por: Jung, Hee-Dam, et al.
Publicado: (2011)

Complex translocation (8;8;21) with additional trisomy 4 in acute myelogenous leukemia
por: Lee, Jae-Hee, et al.
Publicado: (2010)

Prevalence of BCR-ABL T315I Mutation in Malaysian Patients with Imatinib-Resistant Chronic Myeloid Leukemia
por: Yusoff, Yuslina Mat, et al.
Publicado: (2018)

Post-transplant immunotherapy with WT1-specific CTLs for high-risk acute myelogenous leukemia: a prospective clinical phase I/II trial
por: Kim, Hee-Je, et al.
Publicado: (2018)

Overexpression of P-glycoprotein induces acquired resistance to imatinib in chronic myelogenous leukemia cells
por: Peng, Xing-Xiang, et al.
Publicado: (2012)

Concomitant imatinib and ibrutinib in a patient with chronic myelogenous leukemia and chronic lymphocytic leukemia
por: Shea, Lauren K., et al.
Publicado: (2017)

Mesenchymal soluble factors confer imatinib drug resistance in chronic myelogenous leukemia cells
por: Regev, Ofer, et al.
Publicado: (2020)

Ketoconazole Reverses Imatinib Resistance in Human Chronic Myelogenous Leukemia K562 Cells
por: Prado-Carrillo, Omar, et al.
Publicado: (2022)

Verification of the Necessity of the Tolyl Group of PF-543 for Sphingosine Kinase 1 Inhibitory Activity
por: Kim, Su Bin, et al.
Publicado: (2020)

ANGPTL4 exacerbates pancreatitis by augmenting acinar cell injury through upregulation of C5a
por: Jung, Kyung Hee, et al.
Publicado: (2020)

Concurrent Male Gynecomastia and Testicular Hydrocele after Imatinib Mesylate Treatment of a Gastrointestinal Stromal Tumor
por: Kim, Hawk, et al.
Publicado: (2005)

Sensitivity of imatinib-resistant T315I BCR-ABL CML to a synergistic combination of ponatinib and forskolin treatment
por: Oaxaca, Derrick M., et al.
Publicado: (2016)

Imatinib-induced apoptosis of gastric cancer cells is mediated by endoplasmic reticulum stress
por: Kim, Jung Lim, et al.
Publicado: (2019)

Improvement of platelet dysfunction in chronic myelogenous leukemia following treatment with imatinib: a case report
por: Shimabukuro-Vornhagen, Alexander, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_734tmgm5o057tt7b1vv0r4qf8o